However, the inhibition of DGKG expression in hepatic ECs has been shown to reduce TGF-β1 secretion in the liver, thereby decreasing angiogenesis and immune evasion in hepatocellular carcinoma (HCC). This evidence concerns the gene TGFB1 and hepatocellular carcinoma.